Market revenue in 2021 | USD 6.0 billion |
Market revenue in 2030 | USD 10.7 billion |
Growth rate | 6.7% (CAGR from 2021 to 2030) |
Largest segment | Anti-hypertensive |
Fastest growing segment | Anti-hypertensive |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD billion |
Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15% in 2021. Horizon Databook has segmented the South Korea branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
The market is expected to grow with a lucrative growth rate over the forecast period due to opportunities for generic manufacturers and attractive drug pricing policies for the products. An article published in June 2020 suggested that OECD countries use 70% of generics from the total medicines used.
The government of South Korea is focusing on reduction of the prices of generic products and expand their usage to reduce the total healthcare expenditure on pharmaceuticals.
Currently, the prices of generics are found to be around 53.5% lower than the originator drug. However, the price capping on the products could negatively impact the market and opportunities for branded generic players, impeding market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea branded generics market , including forecasts for subscribers. This country databook contains high-level insights into South Korea branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account